Agios Pharmaceuticals AGIO Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's unrealized losses on investments (before tax)?
- Agios Pharmaceuticals (AGIO) reported unrealized losses on investments (before tax) of $1.04M in Q1 2026.
- How has Agios Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- Agios Pharmaceuticals's unrealized losses on investments (before tax) increased by 11.1% year-over-year, from $933K to $1.04M.
- What is the long-term trend for Agios Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -22.3% compound annual growth rate (CAGR), from $216K to $61K.